Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Journal of Clinical Pharmacology
|
August 15, 2015
Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects
Yvonne Y Lau, Wen Gu, Tiffany Lin, et al.
Cancer Chemotherapy and Pharmacology
|
April 21, 2017
Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer
Yvonne Y Lau, Wen Gu, Tiffany Lin, et al.
Cancer Chemotherapy and Pharmacology
|
September 7, 2014
The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors
Sunil Sharma, Carolyn D Britten, Joanne Mortimer, et al.
Cancer Chemotherapy and Pharmacology
|
February 5, 2015
A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258)
Jeffrey R Infante, Ramesh K Ramanathan, Daniel George, et al.
Leukemia Research
|
August 3, 2010
The deacetylase inhibitor LAQ824 induces notch signalling in haematopoietic progenitor cells
Kerstin Schwarz, Annette Romanski, Elena Puccetti, et al.
Cancer Chemotherapy and Pharmacology
|
November 5, 2017
A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors
Vincent A de Weger, Sanjay Goel, Roger von Moos, et al.
European Journal of Haematology
|
November 18, 2014
Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation
Christof Scheid, Donna Reece, Meral Beksac, et al.
British Journal of Haematology
|
August 12, 2009
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma
Michael Dickinson, David Ritchie, Daniel J DeAngelo, et al.
Investigational New Drugs
|
April 17, 2013
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors
Sunil Sharma, Elisabeth G de Vries, Jeffrey R Infante, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2008
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors
Johann S de Bono, Rebecca Kristeleit, Anthony Tolcher, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Journal of Clinical Pharmacology
|
August 15, 2015
Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects
Yvonne Y Lau, Wen Gu, Tiffany Lin, et al.
Cancer Chemotherapy and Pharmacology
|
April 21, 2017
Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer
Yvonne Y Lau, Wen Gu, Tiffany Lin, et al.
Cancer Chemotherapy and Pharmacology
|
September 7, 2014
The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors
Sunil Sharma, Carolyn D Britten, Joanne Mortimer, et al.
Cancer Chemotherapy and Pharmacology
|
February 5, 2015
A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258)
Jeffrey R Infante, Ramesh K Ramanathan, Daniel George, et al.
Leukemia Research
|
August 3, 2010
The deacetylase inhibitor LAQ824 induces notch signalling in haematopoietic progenitor cells
Kerstin Schwarz, Annette Romanski, Elena Puccetti, et al.
Cancer Chemotherapy and Pharmacology
|
November 5, 2017
A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors
Vincent A de Weger, Sanjay Goel, Roger von Moos, et al.
European Journal of Haematology
|
November 18, 2014
Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation
Christof Scheid, Donna Reece, Meral Beksac, et al.
British Journal of Haematology
|
August 12, 2009
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma
Michael Dickinson, David Ritchie, Daniel J DeAngelo, et al.
Investigational New Drugs
|
April 17, 2013
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors
Sunil Sharma, Elisabeth G de Vries, Jeffrey R Infante, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2008
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors
Johann S de Bono, Rebecca Kristeleit, Anthony Tolcher, et al.
Page
of 2